Evidence map›Paper›PMID 39680035›Full record

ArticleACS chemical neuroscience2025

Pilot Screening of TREM1 Inhibitors in Cell-Based Reporter Assays Reflecting TREM1/DAP12 Receptor Assembly and Functionality.

Natalia Filippova, Roman Hromov, James Shi, Peter H King, Louis B Nabors

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Natalia FilippovaDepartment of Neurology, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States.ORCID 0000-0003-2128-5511
Roman HromovEnamine US Inc, South Brunswick Township, New Jersey 08852, United States.
James ShiCollege of Arts and Sciences, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States.
Peter H KingDepartment of Neurology and Center of Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35017, United States.
Louis B NaborsDepartment of Neurology, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States.

Funding

ELAVL1 role in glioblastoma heterogeneity through intercellular gene transfer mediated by cell fusion and tunneling membrane nanotube formationR01CA269365 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Natalia Filippova, Louis B Nabors · 2023 to 2026
$1.3M
NCI NIH HHS R01 CA269365
6 · The paper itself

Abstract

Proinflammatory TREM1 receptors expressed on myeloid-derived cells have recently been recognized as a new oncogenic target in cancer, including gliomas. They are established chemotherapeutic targets in neurodegenerative Parkinson's and Alzheimer's diseases, and they also contribute to stroke and sepsis severities. TREM1 activation requires the TREM1/DAP12 interaction for receptor clustering and signal transduction coordinated by TREM1 ligands. Here, we established the quantitative cell-based high-throughput split luciferase assays of DAP12 dimerization, TREM1 dimerization, and TREM1/DAP12 interaction that allow screening of the inhibitory compounds with quantitative dose-responses, IC

Indexed as

Adaptor Proteins, Signal TransducingTriggering Receptor Expressed on Myeloid Cells-1Drug Evaluation, PreclinicalHEK293 CellsHigh-Throughput Screening AssaysHumansMembrane ProteinsPilot ProjectsReceptors, ImmunologicAdaptor Proteins, Signal TransducingMembrane ProteinsReceptors, ImmunologicTREM1 protein, humanTriggering Receptor Expressed on Myeloid Cells-1TYROBP protein, humancytokinesDAP12inhibitorsneuroinflammationreporter assaysTREM1

Identifiers

PMID39680035
PMCPMC12927207

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.